Tranexamic acid

From Wikipedia, the free encyclopedia


Tranexamic acid
Systematic (IUPAC) name
4-(aminomethyl)cyclohexane-1-carboxylic acid
Identifiers
CAS number	1197-18-8
ATC code	B02AA02
PubChem	5526
DrugBank	APRD01270
Chemical data
Formula	C₈H₁₅N O₂
Mol. mass	157.21 g/mol
Pharmacokinetic data
Bioavailability	34%
Metabolism	?
Half life	3.1 hours
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Injection and oral

Tranexamic acid (commonly marketed as Cyklokapron in the U.S. and as Transamin in Asia) is often prescribed for excessive bleeding. It is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, a molecule responsible for the degradation of fibrin. Fibrin is the basic framework for the formation of a blood clot in hemostasis. It has roughly 8 times the antifibrinolytic activity of an older analogue, ε-aminoacaproic acid.

1 Therapeutic uses
2 References

[edit] Therapeutic uses

[edit] Menstrual bleeding

Tranexamic acid is commonly used to treat certain types of excessive menstrual bleeding, otherwise known as menorrhagia. UK studies have found that women suffering from menorrhagia often have elevated levels of tissue plasminogen activator, an enzyme responsible for the conversion of plasminogen into plasmin

[edit] Haemophilia

Tranexamic acid is also useful in the treatment of bleeding as a second line treatment next to factor VIII in haemophilia patients (i.e. Tooth extraction in haemophilia patients.

[edit] Angioedema

In acquired angioedema types I and II and non-histaminergic angioedema, antifibrinolytics such as tranexamic acid or ε-aminocaproic acid may be effective.